uniQure N.V. (QURE)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Netherlands
Exchange: NASDAQ
Market cap: $3.05B
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Latest financial period: March 31, 2026
Filed with the SEC: May 5, 2026
Estimated earnings date: November 9, 2026
Profit #1437 of 1483 companies
| | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|
| ROE/ROA | 2.2% | 2.1% | 2.3% | 2.0% |
Growth #1386 of 1483 companies
Payout #1116 of 1483 companies
Safety #1449 of 1483 companies
Price #1425 of 1483 companies
